Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol.
[1][2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation.
[1] Bempedoic acid works by blocking an enzyme in the liver called adenosine triphosphate citrate lyase, which is involved in making cholesterol.
[4][2] In the United States, bempedoic acid/ezetimibe is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.[1] In the European Union, bempedoic acid/ezetimibe is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:[2] In the EU it must not be used in pregnant or breast-feeding women.
[2] A phase III study found that bempedoic acid/ezetimibe lowered LDL-C by 39.2% compared to placebo in patients not taking statins.